miR-374a-5p inhibits non-small cell lung cancer cell proliferation and migration via targeting NCK1.

NCK adaptor protein 1 microRNA-374a-5p non-small cell lung cancer tumor suppressor

Journal

Experimental and therapeutic medicine
ISSN: 1792-1015
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 02 08 2019
accepted: 16 04 2021
entrez: 26 7 2021
pubmed: 27 7 2021
medline: 27 7 2021
Statut: ppublish

Résumé

Emerging studies have indicated that microRNAs (miRNAs/miRs) are involved in regulating non-small cell lung cancer (NSCLC)-associated processes. The present study aimed to evaluate the biological roles of miR-374a-5p in NSCLC. Using reverse transcription-quantitative PCR, the expression levels of miR-374a-5p were determined in NSCLC cells and a normal cell line. Functional experiments were performed to investigate the functions of miR-374a-5p in NSCLC. A luciferase activity reporter assay and rescue experiments were performed to validate NCK adaptor protein 1 (NCK1) as a functional target of miR-374a-5p. It was demonstrated that miR-374a-5p levels were decreased in NSCLC cell lines compared with those in a normal cell line. Furthermore, overexpression of miR-374a-5p inhibited NSCLC cell proliferation and migration

Identifiants

pubmed: 34306207
doi: 10.3892/etm.2021.10375
pii: ETM-0-0-10375
pmc: PMC8281440
doi:

Types de publication

Journal Article

Langues

eng

Pagination

943

Informations de copyright

Copyright: © Guo et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

Gynecol Oncol. 2019 Feb;152(2):387-395
pubmed: 30442385
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Cell Biochem. 2019 Sep;120(9):14562-14572
pubmed: 31017716
Front Biosci (Landmark Ed). 2012 Jun 01;17:2508-40
pubmed: 22652795
PLoS One. 2015 Mar 16;10(3):e0121499
pubmed: 25775010
Cell Signal. 2017 Aug;36:67-78
pubmed: 28455144
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Mol Med Rep. 2019 Jul;20(1):604-612
pubmed: 31180541
J Cancer. 2019 Jun 2;10(11):2472-2479
pubmed: 31258753
Mol Med Rep. 2019 Jul;20(1):151-161
pubmed: 31115507
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Dev Biol. 2007 Feb 1;302(1):1-12
pubmed: 16989803
Cancer Lett. 2019 Jul 10;454:224-233
pubmed: 31004703

Auteurs

Qiang Guo (Q)

Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.
Department of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China.

Haijun Wang (H)

Department of Thoracic Surgery, Xingtai People's Hospital, Xingtai, Hebei 054000, P.R. China.

Yanzhao Xu (Y)

Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.

Mingbo Wang (M)

Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.

Ziqiang Tian (Z)

Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.

Classifications MeSH